Subgroup Analyses of EMPOWER-LUNG 1

Panelists discuss how subgroup analyses of the EMPOWER-Lung 1 study assessed the efficacy of pembrolizumab across various patient groups, including those with different PD-L1 expression levels, tumor histology and prior therapies. Results demonstrated consistent survival benefits, highlighting pembrolizumab’s broad clinical applicability in advanced non-small cell lung cancer (NSCLC).